AstraZeneca cans cancer pipeline efforts

AstraZeneca facility at The Cove

In its fourth-quarter earnings out early Friday morning, U.K.-based Big Pharma AstraZeneca has cut two early-stage experimental meds.

The two axed drugs (PDF) are both aimed at cancer targets: The first is MEDI7247, an anti-ASCT2 antibody-drug conjugate, and an oleclumab plus AZD4635 CD73 and A2A inhibitor combo.

MEDI7247 was being directed against both solid and blood cancers and works by binding to ASCT2, which ultimately causes cell death. The drug had been in phase 1 tests in patients with selected relapsed/refractory hematological malignancies including acute myeloid leukemia, multiple myeloma and diffuse large B-cell lymphoma.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Also in phase 1 was oleclumab in combo with AZD4635 targeting non-small cell lung cancer patients with an EGFR mutation.

Although much of its pipeline promise exists in drugs already approved, there were some experimental highlights moving into midstage testing, including two for cancer: selective estrogen receptor degrader AZD9833 for ER-positive breast cancer and PD-1/CTLA-4 bispecific mAb MEDI5752 for solid tumors.

There’s also AstraZeneca's GLP-1/glucagon dual agonist cotadutide for nonalcoholic steatohepatitis and its IL-33 mAb MEDI3506 for diabetic kidney disease and atopic dermatitis, which have made it past the first clinical hurdles.

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.